Myongji Hospital said Thursday that it signed an open innovation agreement with ATGen Group to jointly develop the next generation anticancer immune cell therapy and conduct technology exchanges.
|Myongji Hospital Chairman Lee Wang-jun (third from left in front row) and ATGen Group CEO Park Sang-woo (at Lee’s left) pose for photographers after signing the open innovation agreement at the hospital’s New Horizon Healing Center in Goyang, Gyeonggi Province, on Wednesday.|
Under this agreement, Myongji Hospital and ATGen Group will promote the development of the medical industry and technology, by conducting research and development of anti-cancer immunotherapeutic drugs.
The agreement includes joint R&D, technology exchange, joint use of equipment and facilities, exchange of R&D personnel, holding international conferences and seminars, and conducting joint clinical trials.
“The cooperation with a new bio company, which has a basis in hospital platform, has allowed the realization of the goal of the Myongji New Horizon Cancer Research Institute -- open innovation,” Myongji Hospital Chairman Lee Wang-jun said. “Through this agreement, we hope to create synergies in building a new-horizon ecosystem that harmonizes both the medical and biotechnology sectors.”
ATGen Group CEO Park Sang-woo agreed, saying, “Collaboration between ATGen Group, which has its development technology, and Myongji Hospital, which has clinical know-how and research infrastructure, will accelerate the development of excellent treatments.
<© Korea Biomedical Review, All rights reserved.>